These innovative therapies , Semaglutide , represent a groundbreaking advancement in managing type 2 diabetes and possibly associated disorders. These drugs are categorized as GLP-1 pathway stimulators, indicating these substances to emulate the natural GLP-1 hormone , boosting glucose secretion and suppressing food intake. Although Retatrutide eac